Healthcare News | BioTuesdays by Kilmer Lucas IR

Developments

Anika Therapeutics launches TACTOSET bone repair therapy in the U.S.

Anika Therapeutics (NASDAQ: ANIK) launched its injectable hyaluronic acid (HA) enhanced bone repair therapy, TACTOSET, in the U.S. for the treatment of bone voids and other bone defects. TACTOSET is an injectable, HA...

September 18, 2019

Developments

FDA approves Kadmon Holdings’ generic Wilson’s disease drug

The FDA approved Kadmon Holdings’ (NYSE:KDMN) generic trientine hydrochloride capsules for the treatment of Wilson’s disease patients who are intolerant of penicillamine. Wilson’s disease is a genetic disorder caused by...

September 18, 2019

Executive Moves

MDBriefCase names Drs. David Strain and Mohamed Farghaly as new expert advisors

Online continuing professional development provider, MDBriefCase Group (MDBC), is collaborating with Dr. David Strain, senior clinical lecturer at the University of Exeter and Dr. Mohamed Farghaly, associate professor...

September 18, 2019

Developments

Trendlines OrthoSpin receives FDA clearance for robotic orthopedic treatments

OrthoSpin, a portfolio of company of The Trendlines Group (OTCQX:TRNLY; SGX:42T) received regulatory clearance from the FDA for its smart, robotic external fixation system for orthopedic treatments. The use of external...

September 18, 2019

Developments

Titan Pharma gets second year of NIDA funding for nalmefene implant development

The National Institutes of Health’s National Institute on Drug Abuse (NIDA) approved $6.1-million in second-year funding for Titan Pharmaceuticals‘ (NASDAQ:TTNP) development of a nalmefene implant. Titan is using...

September 18, 2019

Markets

WB starts Axsome Therapeutics at OP; fair value estimate $48

William Blair initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with an “outperform” rating and a fair value estimate of $48. The stock closed at $28.21 on Sept. 17. Axsome Therapeutics is focused on developing...

September 18, 2019

Executive Moves

Stereotaxis names Kimberly Peery as CFO

Stereotaxis (NYSE American:STXS) appointed Kimberly Peery as CFO, effective October 1, replacing Martin Stammer, who has accepted a position as CFO of a large professional services firm in the St. Louis area. He will...

September 18, 2019

Markets

WB starts Minerva Neurosciences at OP; fair value estimate $26

William Blair launched coverage of Minerva Neurosciences (NASDAQ:NERV) with an “outperform” rating and fair value estimate of $26. The stock closed at $8.11 on Sept. 17. Minerva is developing therapies for mood...

September 18, 2019

Developments

iBio expands collaboration with AzarGen to develop plant-made rituximab

iBio (NYSE AMERICAN:IBIO) advanced its collaboration with closely-held AzarGen Biotechnologies by initiating development of a plant-made rituximab for the South African market. iBio previously used its FastPharming...

September 17, 2019

Developments

Concert Pharma completes enrollment in second open label alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its second open label trial comparing once-daily versus twice-daily dosing of CTP-543, a deuterium-modified ruxolitinib, in alopecia areata patients...

September 17, 2019

Anika Therapeutics launches TACTOSET bone repair therapy in the U.S.

FDA approves Kadmon Holdings’ generic Wilson’s disease drug

MDBriefCase names Drs. David Strain and Mohamed Farghaly as new expert advisors

Trendlines OrthoSpin receives FDA clearance for robotic orthopedic treatments

Titan Pharma gets second year of NIDA funding for nalmefene implant development

WB starts Axsome Therapeutics at OP; fair value estimate $48

Stereotaxis names Kimberly Peery as CFO

WB starts Minerva Neurosciences at OP; fair value estimate $26

iBio expands collaboration with AzarGen to develop plant-made rituximab

Concert Pharma completes enrollment in second open label alopecia areata trial

Follow Us

Subscribe

General

More

Subscribe